ATC Group: J04BA01 Clofazimine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J04BA01 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J04 Antimycobacterials
3 J04B Drugs for treatment of lepra
4 J04BA Drugs for treatment of lepra
5 J04BA01 Clofazimine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code Route Amount Notes
ORAL Oral 0.1 g

Active ingredients in J04BA01

Active Ingredient

Clofazimine is an antimycobacterial drug. Clofazimine exerts a slow bactericidal effect on Mycobacterium leprae (Hansen’s bacillus). Clofazimine inhibits mycobacterial growth and binds preferentially to mycobacterial DNA.

Related product monographs

Document Type Information Source  
 LAMPRENE Soft gelatin capsule MPI, Generic Health Products Regulatory Authority (ZA)

Medicines in this ATC group

Estonia (EE)

France (FR)

Japan (JP)

Lithuania (LT)

Malta (MT)

South Africa (ZA)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.